CRISPR Therapeutics vs Laverock Therapeutics
CRISPR Therapeutics vs Laverock Therapeutics, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CRISPR Therapeutics is on 64/100 and Laverock Therapeutics on 41/100.
Where each one leads
CRISPR Therapeutics
- our overall score: 64/100 against 41/100
- agent readiness: 44/100 against 29/100
- domain rating: 67/100 against 19/100
- funding raised: $547M against $10.0M
Laverock Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CRISPR Therapeutics | Laverock Therapeutics |
|---|---|---|
| What it is | Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology. | Developing disease-responsive advanced therapies through programmable gene control technology. |
| Category | Biotechnology, Gene Editing, Therapeutics, Pharmaceuticals | Biotechnology, Gene Therapy, Drug Delivery, Healthcare |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2013 | 2020 |
| Headquarters | Zug, Switzerland | Cambridge, United Kingdom |
| Status | Active | Active |
Size, funding and growth
| Measure | CRISPR Therapeutics | Laverock Therapeutics |
|---|---|---|
| Total funding | $547M | $10.0M |
| Latest round | Series B | Seed |
| Valuation | Not published | $1.1B |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CRISPR Therapeutics | Laverock Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 64/100 | 41/100 |
| Traction | 40/100 | 35/100 |
| Team | 70/100 | Not published |
| Search visibility | 13/100 | 3/100 |
| Quality | 88/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (44/100) | F (29/100) |
| Domain ratingLink authority, 0-100 | 67/100 | 19/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CRISPR Therapeutics | Laverock Therapeutics |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | Not detected | Webflow |
| Frameworks | Jquery | Not detected |
| Analytics | Google Analytics 4 | Google Tag Manager |
CRISPR Therapeutics vs Laverock Therapeutics: common questions
Which is better, CRISPR Therapeutics or Laverock Therapeutics?
On our 0-100 score CRISPR Therapeutics rates higher (64/100 against 41/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do CRISPR Therapeutics and Laverock Therapeutics compare on the numbers?
CRISPR Therapeutics leads on our overall score (64/100 against 41/100), agent readiness (44/100 against 29/100), domain rating (67/100 against 19/100), funding raised ($547M against $10.0M).
Read the full CRISPR Therapeutics review and pricing or the Laverock Therapeutics review and pricing. You can also browse other CRISPR Therapeutics alternatives we track.